Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review

References

• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–943.
   PubMed Web of Science ®Google Scholar
• Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135:511–518.
   PubMed Web of Science ®Google Scholar
• Gamalero L, Simonini G, Ferrara G, et al. Evidence-based treatment for uveitis. Isr Med Assoc J. 2019;21:475–479.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum. 2019;49:438–445.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192.
   PubMed Web of Science ®Google Scholar
• Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediators Inflamm. 2019;2019:1623847.
   PubMed Web of Science ®Google Scholar
• Silvestri E, Bitossi A, Bettiol A, et al. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behcet’s syndrome. Inflammopharmacology. 2020;28:711–718.
   PubMed Web of Science ®Google Scholar
• Martin-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term follow-up and optimization of infliximab in refractory uveitis due to Behcet disease: national study of 103 white patients. J Rheumatol. 2021;48:741–750.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behcet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71:2081–2089.
   PubMed Web of Science ®Google Scholar
• Leclercq M, Desbois AC, Domont F, et al. Biotherapies in uveitis. J Clin Med. 2020;9:3599.
   PubMed Web of Science ®Google Scholar
• Atiqi S, Hooijberg F, Loeff FC, et al. Immunogenicity of TNF-inhibitors. Front Immunol. 2020;11:312.
   PubMed Web of Science ®Google Scholar
• Simonini G, Cimaz R, Jones GT, et al. Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: the current evidence from a systematic review. Semin Arthritis Rheum. 2015;45:238–250.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Prieto-Pena D, Vicente-Rabaneda EF, et al. Utility of tocilizumab in autoimmune eye diseases. Expert Opin Biol Ther. 2022;22:789–799.
   PubMed Web of Science ®Google Scholar
• Ng CC, Sy A, Cunningham ET Jr. Rituximab for non-infectious uveitis and scleritis. J Ophthalmic Inflamm Infect. 2021;11:23.
   PubMed Web of Science ®Google Scholar
• Gupta S, Shyamsundar K, Agrawal M, et al. Current knowledge of biologics in treatment of noninfectious uveitis. J Ocul Pharmacol Ther. 2022;38:203–222.
   PubMed Web of Science ®Google Scholar
• Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18:2127–2133.
   PubMedGoogle Scholar
• Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Beltran E, Hernandez-Garfella M, et al. Tocilizumab in Behcet’s disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. Clin Exp Rheumatol. 2021;39 Suppl 132:37–42. doi: 10.55563/clinexprheumatol/9ipkcs.
   PubMed Web of Science ®Google Scholar
• Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis. Ocul Immunol Inflamm. 2021;29:14–20.
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calvo-Rio V, Mesquida M, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter Study of 25 Patients. Am J Ophthalmol. 2019;200:85–94.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Calvo-Rio V, Beltran E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57:856–864.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-Interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69:668–675. .
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;25:215–220.
   PubMed Web of Science ®Google Scholar
• Casas LD, Calvo-Río V, Calvo I, et al. OP0059 Golimumab versus tocilizumab for severe and refractory juvenile idiopathic arthritis-uveitis. multicenter study of 33 patients. Annals of the Rheumatic Diseases. 2017;76:75–76.
   Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenc V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361–1370.
   PubMed Web of Science ®Google Scholar
• Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2018;26:1005–1014.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94:e400–6.
   PubMed Web of Science ®Google Scholar
• Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Efficacy of tocilizumab in patients with uveitis refractory to other biologic drugs: a multicenter study on 31 cases. 2014 ACR/ARHP Annual Meeting, Boston, MA, November 14-19, 2014; 2014.
   Google Scholar
• Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100:782–786.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50:1390–1394.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–252. .
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmol. 2013;120:777–787.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:191–197.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) outcomes of the STOP-Uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.
   PubMed Web of Science ®Google Scholar